1
|
Cimino C, Sánchez López E, Bonaccorso A, Bonilla L, Musumeci T, Badia J, Baldomà L, Pignatello R, Marrazzo A, Barbaraci C, García ML, Carbone C. In vitro and in vivo studies of ocular topically administered NLC for the treatment of uveal melanoma. Int J Pharm 2024; 660:124300. [PMID: 38851409 DOI: 10.1016/j.ijpharm.2024.124300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2024] [Revised: 05/08/2024] [Accepted: 05/31/2024] [Indexed: 06/10/2024]
Abstract
Uveal melanoma is one of the most common and aggressive intraocular malignancies, and, due to its great capability of metastasize, it constitutes the most incident intraocular tumor in adults. However, to date there is no effective treatment since achieving the inner ocular tissues still constitutes one of the greatest challenges in actual medicine, because of the complex structure and barriers. Uncoated and PEGylated nanostructured lipid carriers were developed to achieve physico-chemical properties (mean particle size, homogeneity, zeta potential, pH and osmolality) compatible for the ophthalmic administration of (S)-(-)-MRJF22, a new custom-synthetized prodrug for the potential treatment of uveal melanoma. The colloidal physical stability was investigated at different temperatures by Turbiscan® Ageing Station. Morphology analysis and mucoadhesive studies highlighted the presence of small particles suitable to be topically administered on the ocular surface. In vitro release studies performed using Franz diffusion cells demonstrated that the systems were able to provide a slow and prolonged prodrug release. In vitro cytotoxicity test on Human Corneal Epithelium and Human Uveal Melanoma cell lines and Hen's egg-chorioallantoic membrane test showed a dose-dependent cytotoxic effect of the free prodrug on corneal cells, whose cytocompatibility improved when encapsulated into nanoparticles, as also confirmed by in vivo studies on New Zealand albino rabbits. Antiangiogenic capability and preventive anti-inflammatory properties were also investigated on embryonated eggs and rabbits, respectively. Furthermore, preliminary in vivo biodistribution images of fluorescent nanoparticles after topical instillation in rabbits' eyes, suggested their ability to reach the posterior segment of the eye, as a promising strategy for the treatment of choroidal uveal melanoma.
Collapse
Affiliation(s)
- Cinzia Cimino
- PhD in Biotechnology, Department of Biomedical and Biotechnological Sciences, University of Catania, Via Santa Sofia 97, 95123 Catania, Italy; Laboratory of Drug Delivery Technology, Department of Drug and Health Sciences, University of Catania, Via Valdisavoia 5, 95123 Catania, Italy; Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028, Barcelona, Spain; NANOMED, Research Centre for Nanomedicine and Pharmaceutical Nanotechnology, University of Catania
| | - Elena Sánchez López
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028, Barcelona, Spain; Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028, Barcelona, Spain; Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, 08034, Barcelona, Spain
| | - Angela Bonaccorso
- Laboratory of Drug Delivery Technology, Department of Drug and Health Sciences, University of Catania, Via Valdisavoia 5, 95123 Catania, Italy; NANOMED, Research Centre for Nanomedicine and Pharmaceutical Nanotechnology, University of Catania
| | - Lorena Bonilla
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028, Barcelona, Spain; Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028, Barcelona, Spain
| | - Teresa Musumeci
- Laboratory of Drug Delivery Technology, Department of Drug and Health Sciences, University of Catania, Via Valdisavoia 5, 95123 Catania, Italy; NANOMED, Research Centre for Nanomedicine and Pharmaceutical Nanotechnology, University of Catania
| | - Josefa Badia
- Department of Biochemistry and Physiology, Biochemistry and Biomolecular Science, University of Barcelona, 08028 Barcelona, Spain; Institute of Biomedicine of the University of Barcelona (IBUB), 08028 Barcelona, Spain; Research Institute Sant Joan De Déu (IR-SJD), 08950 Barcelona, Spain
| | - Laura Baldomà
- Department of Biochemistry and Physiology, Biochemistry and Biomolecular Science, University of Barcelona, 08028 Barcelona, Spain; Institute of Biomedicine of the University of Barcelona (IBUB), 08028 Barcelona, Spain; Research Institute Sant Joan De Déu (IR-SJD), 08950 Barcelona, Spain
| | - Rosario Pignatello
- Laboratory of Drug Delivery Technology, Department of Drug and Health Sciences, University of Catania, Via Valdisavoia 5, 95123 Catania, Italy; NANOMED, Research Centre for Nanomedicine and Pharmaceutical Nanotechnology, University of Catania
| | - Agostino Marrazzo
- Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, 08034, Barcelona, Spain; Medicinal Chemistry Laboratory, Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95124 Catania, Italy
| | - Carla Barbaraci
- Medicinal Chemistry Laboratory, Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95124 Catania, Italy; Present address: Laboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain
| | - María Luisa García
- Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028, Barcelona, Spain; Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028, Barcelona, Spain
| | - Claudia Carbone
- Laboratory of Drug Delivery Technology, Department of Drug and Health Sciences, University of Catania, Via Valdisavoia 5, 95123 Catania, Italy; NANOMED, Research Centre for Nanomedicine and Pharmaceutical Nanotechnology, University of Catania.
| |
Collapse
|
2
|
Lombardo R, Ruponen M, Rautio J, Ghelardini C, Di Cesare Mannelli L, Calosi L, Bani D, Lampinen R, Kanninen KM, Koivisto AM, Penttilä E, Löppönen H, Pignatello R. Development of Lyophilised Eudragit ® Retard Nanoparticles for the Sustained Release of Clozapine via Intranasal Administration. Pharmaceutics 2023; 15:pharmaceutics15051554. [PMID: 37242796 DOI: 10.3390/pharmaceutics15051554] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Revised: 05/12/2023] [Accepted: 05/17/2023] [Indexed: 05/28/2023] Open
Abstract
Clozapine (CZP) is the only effective drug in schizophrenia resistant to typical antipsychotics. However, existing dosage forms (oral or orodispersible tablets, suspensions or intramuscular injection) show challenging limitations. After oral administration, CZP has low bioavailability due to a large first-pass effect, while the i.m. route is often painful, with low patient compliance and requiring specialised personnel. Moreover, CZP has a very low aqueous solubility. This study proposes the intranasal route as an alternative route of administration for CZP, through its encapsulation in polymeric nanoparticles (NPs) based on Eudragit® RS100 and RL100 copolymers. Slow-release polymeric NPs with dimensions around 400-500 nm were formulated to reside and release CZP in the nasal cavity, where it can be absorbed through the nasal mucosa and reach the systemic circulation. CZP-EUD-NPs showed a controlled release of CZP for up to 8 h. Furthermore, to reduce mucociliary clearance and increase the residence time of NPs in the nasal cavity to improve drug bioavailability, mucoadhesive NPs were formulated. This study shows that the NPs already exhibited strong electrostatic interactions with mucin at time zero due to the presence of the positive charge of the used copolymers. Furthermore, to improve the solubility, diffusion and adsorption of CZPs and the storage stability of the formulation, it was lyophilised using 5% (w/v) HP-β-CD as a cryoprotectant. It ensured the preservation of the NPs' size, PDI and charge upon reconstitution. Moreover, physicochemical characterisation studies of solid-state NPs were performed. Finally, toxicity studies were performed in vitro on MDCKII cells and primary human olfactory mucosa cells and in vivo on the nasal mucosa of CD-1 mice. The latter showed non-toxicity of B-EUD-NPs and mild CZP-EUD-NP-induced tissue abnormalities.
Collapse
Affiliation(s)
- Rosamaria Lombardo
- Laboratory of Drug Delivery Technology, Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy
| | - Marika Ruponen
- School of Pharmacy, University of Eastern Finland, Yliopistonranta 1C, 70210 Kuopio, Finland
| | - Jarkko Rautio
- School of Pharmacy, University of Eastern Finland, Yliopistonranta 1C, 70210 Kuopio, Finland
| | - Carla Ghelardini
- Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA)-Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy
| | - Lorenzo Di Cesare Mannelli
- Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA)-Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy
| | - Laura Calosi
- Platform of Imaging, Department of Experimental & Clinical Medicine, University of Florence, 50139 Florence, Italy
| | - Daniele Bani
- Platform of Imaging, Department of Experimental & Clinical Medicine, University of Florence, 50139 Florence, Italy
| | - Riikka Lampinen
- A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70210 Kuopio, Finland
| | - Katja M Kanninen
- A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70210 Kuopio, Finland
| | - Anne M Koivisto
- Brain Research Unit, Department of Neurology, School of Medicine, University of Eastern Finland, 70200 Kuopio, Finland
- Department of Neurology, Neuro Centre, Kuopio University Hospital, 70210 Kuopio, Finland
- Department of Neurology and Geriatrics, Helsinki University Hospital and Neurosciences, Faculty of Medcine, University of Helsinki, 00290 Helsinki, Finland
| | - Elina Penttilä
- Department of Otorhinolaryngology, University of Eastern Finland, Kuopio University Hospital, 70210 Kuopio, Finland
| | - Heikki Löppönen
- Department of Otorhinolaryngology, University of Eastern Finland, Kuopio University Hospital, 70210 Kuopio, Finland
| | - Rosario Pignatello
- Laboratory of Drug Delivery Technology, Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy
- NANOMED-Research Centre on Nanomedicine and Pharmaceutical Nanotechnology, University of Catania, Viale A. Doria 6, 95125 Catania, Italy
| |
Collapse
|
3
|
Bonaccorso A, Gigliobianco MR, Lombardo R, Pellitteri R, Di Martino P, Mancuso A, Musumeci T. Nanonized carbamazepine for nose-to-brain delivery: pharmaceutical formulation development. Pharm Dev Technol 2023; 28:248-263. [PMID: 36748759 DOI: 10.1080/10837450.2023.2177673] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Epilepsy is one of the most common neurological disorders in the world. The therapeutic treatment is challenging since conventional drugs have limited efficacy and several side effects that impair patient management. Efforts are being made to find innovative strategies to control epileptic seizures. Intranasal administration provides a convenient route to deliver the drug to the brain. Carbamazepine (CBZ) is an anticonvulsant characterized by poor water solubility, nanonization can improve its bioavailability. Therefore, the design of CBZ nanocrystals (NCs) was assessed to obtain a formulation suitable for nose-to-brain delivery. CBZ NCs were prepared by sonoprecipitation following the Quality by Design approach identifying the impact of process and formulation variables on the critical quality attributes of the final product. The formulation was characterized by a technological point of view (thermotropic behavior, crystallinity, morphology, mucoadhesive strength). Response surface methodology was a reliable tool (error % 2.6) to optimize CBZ NCs with size ≤300 nm. Incubation of CBZ NCs in artificial cerebrospinal fluid at 37 °C did not promote aggregation and degradation phenomena. Preliminary biological studies revealed the biocompatibility of CBZ NCs towards Olfactory Ensheating Cells. The suspension was successfully converted into a powder. The highly concentrated formulation can be obtained, providing the possibility to administer the maximum dose of the drug in the lowest volume.
Collapse
Affiliation(s)
- Angela Bonaccorso
- Department of Drug and Health Sciences, University of Catania, Catania, Italy.,NANOMED - Research Centre for Nanomedicine and Pharmaceutical Nanotechnology, University of Catania, Catania, Italy
| | | | - Rosamaria Lombardo
- Department of Drug and Health Sciences, University of Catania, Catania, Italy
| | - Rosalia Pellitteri
- Institute for Biomedical Research and Innovation, National Research Council, Catania, Italy
| | - Piera Di Martino
- Department of Pharmacy, University of Chieti-Pescara 'G. d'Annunzio', Chieti, Italy
| | - Antonia Mancuso
- Department of Experimental and Clinical Medicine, University of Catanzaro 'Magna Graecia', Catanzaro, Italy
| | - Teresa Musumeci
- Department of Drug and Health Sciences, University of Catania, Catania, Italy.,NANOMED - Research Centre for Nanomedicine and Pharmaceutical Nanotechnology, University of Catania, Catania, Italy
| |
Collapse
|
4
|
Romeo A, Bonaccorso A, Carbone C, Lupo G, Daniela Anfuso C, Giurdanella G, Caggia C, Randazzo C, Russo N, Romano GL, Bucolo C, Rizzo M, Tosi G, Thomas Duskey J, Ruozi B, Pignatello R, Musumeci T. Melatonin loaded hybrid nanomedicine: DoE approach, optimization and in vitro study on diabetic retinopathy model. Int J Pharm 2022; 627:122195. [PMID: 36115466 DOI: 10.1016/j.ijpharm.2022.122195] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 09/03/2022] [Accepted: 09/09/2022] [Indexed: 11/17/2022]
Abstract
Melatonin (MEL) is a pleiotropic neurohormone of increasing interest as a neuroprotective agent in ocular diseases. Improving the mucoadhesiveness is a proposed strategy to increase the bioavailability of topical formulations. Herein, the design and optimization of MEL-loaded lipid-polymer hybrid nanoparticles (mel-LPHNs) using Design of Experiment (DoE) was performed. LPHNs consisted of PLGA-PEG polymer nanoparticles coated with a cationic lipid-shell. The optimized nanomedicine showed suitable size for ophthalmic administration (189.4 nm; PDI 0.260) with a positive surface charge (+39.8 mV), high encapsulation efficiency (79.8 %), suitable pH and osmolarity values, good mucoadhesive properties and a controlled release profile. Differential Scanning Calorimetry and Fourier-Transform Infrared Spectroscopy confirmed the encapsulation of melatonin in the systems and the interaction between lipids and polymer matrix. Biological evaluation in an in vitro model of diabetic retinopathy demonstrated enhanced neuroprotective and antioxidant activities of mel-LPHNs, compared to melatonin aqueous solution at the same concentration (0.1 and 1 μM). A modified Draize test was performed to assess the ocular tolerability of the formulation showing no signs of irritation. To the best our knowledge, this study reported for the first time the development of mel-LPHNs, a novel and safe hybrid platform suitable for the topical management of retinal diseases.
Collapse
Affiliation(s)
- Alessia Romeo
- Department of Drug and Health Sciences, University of Catania, Viale A. Doria, 6 - 95125 Catania, Italy.
| | - Angela Bonaccorso
- Department of Drug and Health Sciences, University of Catania, Viale A. Doria, 6 - 95125 Catania, Italy; Department of Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 97, 95123 Catania, Italy.
| | - Claudia Carbone
- Department of Drug and Health Sciences, University of Catania, Viale A. Doria, 6 - 95125 Catania, Italy; Department of Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 97, 95123 Catania, Italy.
| | - Gabriella Lupo
- Department of Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 97, 95123 Catania, Italy.
| | - Carmelina Daniela Anfuso
- Department of Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 97, 95123 Catania, Italy.
| | - Giovanni Giurdanella
- Department of Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 97, 95123 Catania, Italy.
| | - Cinzia Caggia
- NANO-i, Research Centre for Ocular Nanotechnology, University of Catania, Viale A. Doria 6, 95125 Catania, Italy; Department of Agriculture, Food and Environment (Di3A), University of Catania, Via S. Sofia 100, 95123 Catania, Italy.
| | - Cinzia Randazzo
- NANO-i, Research Centre for Ocular Nanotechnology, University of Catania, Viale A. Doria 6, 95125 Catania, Italy; Department of Agriculture, Food and Environment (Di3A), University of Catania, Via S. Sofia 100, 95123 Catania, Italy.
| | - Nunziatina Russo
- Department of Agriculture, Food and Environment (Di3A), University of Catania, Via S. Sofia 100, 95123 Catania, Italy.
| | - Giovanni Luca Romano
- Department of Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 97, 95123 Catania, Italy.
| | - Claudio Bucolo
- Department of Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 97, 95123 Catania, Italy.
| | - Milena Rizzo
- Department of Drug and Health Sciences, University of Catania, Viale A. Doria, 6 - 95125 Catania, Italy.
| | - Giovanni Tosi
- Department of Life Sciences, Nanotech Lab, Te.Far.T.I., University of Modena & Reggio Emilia, Via Campi 103, Modena 41125, Italy.
| | - Jason Thomas Duskey
- Department of Life Sciences, Nanotech Lab, Te.Far.T.I., University of Modena & Reggio Emilia, Via Campi 103, Modena 41125, Italy.
| | - Barbara Ruozi
- Department of Life Sciences, Nanotech Lab, Te.Far.T.I., University of Modena & Reggio Emilia, Via Campi 103, Modena 41125, Italy.
| | - Rosario Pignatello
- Department of Drug and Health Sciences, University of Catania, Viale A. Doria, 6 - 95125 Catania, Italy; NANO-i, Research Centre for Ocular Nanotechnology, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.
| | - Teresa Musumeci
- Department of Drug and Health Sciences, University of Catania, Viale A. Doria, 6 - 95125 Catania, Italy; NANO-i, Research Centre for Ocular Nanotechnology, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.
| |
Collapse
|
5
|
Almond oil O/W nanoemulsions: Potential application for ocular delivery. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.103424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
6
|
Development of Eudragit® Nanoparticles for Intranasal Drug Delivery: Preliminary Technological and Toxicological Evaluation. APPLIED SCIENCES-BASEL 2022. [DOI: 10.3390/app12052373] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Intranasal administration has assumed in the last years an increasing value as an alternative strategy for the systemic adsorption of drugs, as an alternative to oral and parenteral routes thanks to the high vascularized nasal mucosa. Nevertheless, different drug features may restrict its absorption through the nasal mucosa with an insufficient diffusion to the systemic circulation. Several technological strategies are under investigation to improve drug absorption during nasal formulation design and production. The use of bioadhesive polymers can be considered a valid approach to pursue the aforementioned goal. Based on this consideration, Eudragit® Retard RS100 and RL100 resins were selected as positively charged copolymers to prepare polymeric NPs with potential mucoadhesive properties suitable for intranasal application. NPs were produced by the Quasi-emulsion Solvent Evaporation (QESD) method and loaded with diclofenac acid (DIC) or its epolamine salt (DIEP). Preliminary investigations were performed to obtain the optimized blank formulation and drugs loaded NPs evaluating different parameters that can affect particles size and polydispersity. The optimized formulations unloaded and loaded with DIC and DIEP were further evaluated for their thermotropic behavior by differential scanning calorimetry. Mucoadhesive evaluation was assessed by measuring variation in zeta potential and by turbidimetric assay after incubation of particles with mucin in simulated nasal fluid (SNF) at 37 °C at different time points (0, 1 and 24 h) compared to the pure suspensions. Stability of DIC and DIEP loaded NPs was also evaluated in SNF to predict potential aggregation phenomena after nasal administration. Finally, in vivo experiments showed absence of toxicity on the nasal mucosa of mice.
Collapse
|
7
|
Sorafenib Repurposing for Ophthalmic Delivery by Lipid Nanoparticles: A Preliminary Study. Pharmaceutics 2021; 13:pharmaceutics13111956. [PMID: 34834371 PMCID: PMC8622456 DOI: 10.3390/pharmaceutics13111956] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2021] [Revised: 11/15/2021] [Accepted: 11/16/2021] [Indexed: 12/29/2022] Open
Abstract
Uveal melanoma is the second most common melanoma and the most common intraocular malignant tumour of the eye. Among various treatments currently studied, Sorafenib was also proposed as a promising drug, often administered with other compounds in order to avoid resistance mechanisms. Despite its promising cellular activities, the use of Sorafenib by oral administration is limited by its severe side effects and the difficulty to reach the target. The encapsulation into drug delivery systems represents an interesting strategy to overcome these limits. In this study, different lipid nanoparticulate formulations were prepared and compared in order to select the most suitable for the encapsulation of Sorafenib. In particular, two solid lipids (Softisan or Suppocire) at different concentrations were used to produce solid lipid nanoparticles, demonstrating that higher amounts were able to achieve smaller particle sizes, higher homogeneity, and longer physical stability. The selected formulations, which demonstrated to be biocompatible on Statens Seruminstitut Rabbit Cornea cells, were modified to improve their mucoadhesion, evaluating the effect of two monovalent cationic lipids with two lipophilic chains. Sorafenib encapsulation allowed obtaining a sustained and prolonged drug release, thus confirming the potential use of the developed strategy to topically administer Sorafenib in the treatment of uveal melanoma.
Collapse
|
8
|
Optimization of dextran sulfate/poly-l-lysine based nanogels polyelectrolyte complex for intranasal ovalbumin delivery. J Drug Deliv Sci Technol 2021. [DOI: 10.1016/j.jddst.2021.102678] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Craparo EF, Musumeci T, Bonaccorso A, Pellitteri R, Romeo A, Naletova I, Cucci LM, Cavallaro G, Satriano C. mPEG-PLGA Nanoparticles Labelled with Loaded or Conjugated Rhodamine-B for Potential Nose-to-Brain Delivery. Pharmaceutics 2021; 13:pharmaceutics13091508. [PMID: 34575584 PMCID: PMC8471208 DOI: 10.3390/pharmaceutics13091508] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Revised: 09/03/2021] [Accepted: 09/07/2021] [Indexed: 11/16/2022] Open
Abstract
Nowdays, neurodegenerative diseases represent a great challenge from both the therapeutic and diagnostic points of view. Indeed, several physiological barriers of the body, including the blood brain barrier (BBB), nasal, dermal, and intestinal barriers, interpose between the development of new drugs and their effective administration to reach the target organ or target cells at therapeutic concentrations. Currently, the nose-to-brain delivery with nanoformulations specifically designed for intranasal administration is a strategy widely investigated with the goal to reach the brain while bypassing the BBB. To produce nanosystems suitable to study both in vitro and/or in vivo cells trafficking for potential nose-to-brain delivery route, we prepared and characterized two types of fluorescent poly(ethylene glycol)-methyl-ether-block-poly(lactide-co-glycolide) (PLGA-PEG) nanoparticles (PNPs), i.e., Rhodamine B (RhB) dye loaded- and grafted- PNPs, respectively. The latter were produced by blending into the PLGA-PEG matrix a RhB-labeled polyaspartamide/polylactide graft copolymer to ensure a stable fluorescence during the time of analysis. Photon correlation spectroscopy (PCS), UV-visible (UV-vis) spectroscopies, differential scanning calorimetry (DSC), atomic force microscopy (AFM) were used to characterize the RhB-loaded and RhB-grafted PNPs. To assess their potential use for brain targeting, cytotoxicity tests were carried out on olfactory ensheathing cells (OECs) and neuron-like differentiated PC12 cells. Both PNP types showed mean sizes suitable for nose-to-brain delivery (<200 nm, PDI < 0.3) and were not cytotoxic toward OECs in the concentration range tested, while a reduction in the viability on PC12 cells was found when higher concentrations of nanomedicines were used. Both the RhB-labelled NPs are suitable drug carrier models for exploring cellular trafficking in nose-to-brain delivery for short-time or long-term studies.
Collapse
Affiliation(s)
- Emanuela Fabiola Craparo
- Department of Biological, Chemical and Pharmaceutical Science and Technologies (STEBICEF), 90123 Palermo, Italy; (E.F.C.); (G.C.)
| | - Teresa Musumeci
- Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy; (A.B.); (A.R.)
- Correspondence: ; Tel.: +39-095-738-4021
| | - Angela Bonaccorso
- Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy; (A.B.); (A.R.)
| | - Rosalia Pellitteri
- Institute for Biomedical Research and Innovation, National Research Council, 95126 Catania, Italy;
| | - Alessia Romeo
- Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy; (A.B.); (A.R.)
- PhD in Neuroscience, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy
| | - Irina Naletova
- Inter-University Consortium for Research on the Chemistry of Metal Ions in Biological Systems, University of Bari, 70126 Bari, Italy; (I.N.); (C.S.)
- Institute of Crystallography, Research National Council, 95126 Catania, Italy
| | - Lorena Maria Cucci
- Department of Chemical Science, University of Catania, 95125 Catania, Italy;
| | - Gennara Cavallaro
- Department of Biological, Chemical and Pharmaceutical Science and Technologies (STEBICEF), 90123 Palermo, Italy; (E.F.C.); (G.C.)
| | - Cristina Satriano
- Inter-University Consortium for Research on the Chemistry of Metal Ions in Biological Systems, University of Bari, 70126 Bari, Italy; (I.N.); (C.S.)
- Department of Chemical Science, University of Catania, 95125 Catania, Italy;
| |
Collapse
|
10
|
The Physicochemical, Biopharmaceutical, and In Vitro Efficacy Properties of Freeze-Dried Dexamethasone-Loaded Lipomers. Pharmaceutics 2021; 13:pharmaceutics13081322. [PMID: 34452283 PMCID: PMC8401638 DOI: 10.3390/pharmaceutics13081322] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 08/16/2021] [Accepted: 08/17/2021] [Indexed: 11/17/2022] Open
Abstract
Dexamethasone-loaded polymer hybrid nanoparticles were developed as a potential tool to treat alopecia areata due to their follicular targeting ability. Freeze drying (FD) is a common technique used to improve nanoparticle stability; however, there are few studies focused on its effect on ethyl cellulose lipid-core nanoparticles. Nanoparticles were lyophilized with different cryoprotectants. Sucrose was selected because it allowed for a good resuspension and provided acceptable physicochemical parameters (374.33 nm, +34.7 mV, polydispersion 0.229%, and 98.87% encapsulation efficiency). The nanoparticles obtained were loaded into a pleasant xanthan gum hydrogel, and the rheological, release, and skin permeation profiles of different formulations were studied. The FD formulation significantly modified the particle size, and the drug release and permeation properties were also altered. In addition, analyses of the cytotoxicity and anti-inflammatory efficacy of FD and non-FD particles on human keratinocytes indicated no differences.
Collapse
|
11
|
Essential Oil-Loaded NLC for Potential Intranasal Administration. Pharmaceutics 2021; 13:pharmaceutics13081166. [PMID: 34452126 PMCID: PMC8399280 DOI: 10.3390/pharmaceutics13081166] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 07/23/2021] [Accepted: 07/27/2021] [Indexed: 12/21/2022] Open
Abstract
Complementary and alternative medicines represent an interesting field of research on which worldwide academics are focusing many efforts. In particular, the possibility to exploit pharmaceutical technology strategies, such as the nanoencapsulation, for the delivery of essential oils is emerging as a promising strategy not only in Italy but also all over the world. The aim of this work was the development of nanostructured lipid carriers (NLC) for the delivery of essential oils (Lavandula, Mentha, and Rosmarinus) by intranasal administration, an interesting topic in which Italian contributions have recently increased. Essential oil-loaded NLC, projected as a possible add-on strategy in the treatment of neurodegenerative diseases, were characterized in comparison to control formulations prepared with Tegosoft CT and Neem oil. Homogeneous (polydispersity index, PDI < 0.2) nanoparticles with a small size (<200 nm) and good stability were obtained. Morphological and physical-chemical studies showed the formation of different structures depending on the nature of the liquid oil component. In particular, NLC prepared with Lavandula or Rosmarinus showed the formation of a more ordered structure with higher cytocompatibility on two cell lines, murine and human fibroblasts. Taken together, our preliminary results show that optimized positively charged NLC containing Lavandula or Rosmarinus can be proposed as a potential add-on strategy in the treatment of neurodegenerative diseases through intranasal administration, due to the well-known beneficial effects of essential oils and the mucoadhesive properties of NLC.
Collapse
|
12
|
Lombardo R, Musumeci T, Carbone C, Pignatello R. Nanotechnologies for intranasal drug delivery: an update of literature. Pharm Dev Technol 2021; 26:824-845. [PMID: 34218736 DOI: 10.1080/10837450.2021.1950186] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Scientific research has focused its attention on finding an alternative route to systemic oral and parenteral administration, to overcome their usual drawbacks, such as hepatic first-pass which decreases drug bioavailability after oral administration, off-target effects, low patient compliance and low speed of onset of the pharmacological action in first-aid cases. Innovative drug delivery systems (DDS), mainly based on polymer and lipid biocompatible materials, have given a great prompt in this direction in the last years. The intranasal (IN) route of administration is a valid non-invasive alternative. It is highly suitable for self-administration, the drug quickly reaches the bloodstream, largely avoiding the first pass effect, and can also reach directly the brain bypassing BBB. Association of IN route with DDS can thus become a winning strategy for the controlled delivery of drugs, especially when a very quick effect is desired or needed. This review aims at analyzing the scientific literature regarding IN-DDS and their different ways of administration (systemic, topical, pulmonary, nose-to-brain). In particular, attention was devoted to polymer- and lipid-based micro- and nanocarriers, being the topic of most published articles in the last decade, but the whole plethora of colloidal DDS investigated in recent years for IN administration was presented.
Collapse
Affiliation(s)
- Rosamaria Lombardo
- Department of Drug Sciences, University of Catania, Catania, Italy.,Neurosciences, University of Catania, Catania, Italy
| | - Teresa Musumeci
- Department of Drug Sciences, University of Catania, Catania, Italy.,NANO-i - Research Center for Ocular Nanotechnology, University of Catania, Catania, Italy
| | - Claudia Carbone
- Department of Drug Sciences, University of Catania, Catania, Italy.,NANO-i - Research Center for Ocular Nanotechnology, University of Catania, Catania, Italy
| | - Rosario Pignatello
- Department of Drug Sciences, University of Catania, Catania, Italy.,NANO-i - Research Center for Ocular Nanotechnology, University of Catania, Catania, Italy
| |
Collapse
|
13
|
Ferulic Acid-Loaded Polymeric Nanoparticles for Potential Ocular Delivery. Pharmaceutics 2021; 13:pharmaceutics13050687. [PMID: 34064572 PMCID: PMC8150711 DOI: 10.3390/pharmaceutics13050687] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Revised: 04/30/2021] [Accepted: 05/06/2021] [Indexed: 11/16/2022] Open
Abstract
Ferulic acid (FA) is an antioxidant compound that can prevent ROS-related diseases, but due to its poor solubility, therapeutic efficacy is limited. One strategy to improve the bioavailability is nanomedicine. In the following study, FA delivery through polymeric nanoparticles (NPs) consisting of polylactic acid (NPA) and poly(lactic-co-glycolic acid) (NPB) is proposed. To verify the absence of cytotoxicity of blank carriers, a preliminary in vitro assay was performed on retinal pericytes and endothelial cells. FA-loaded NPs were subjected to purification studies and the physico-hemical properties were analyzed by photon correlation spectroscopy. Encapsulation efficiency and in vitro release studies were assessed through high performance liquid chromatography. To maintain the integrity of the systems, nanoformulations were cryoprotected and freeze-dried. Morphology was evaluated by a scanning electron microscope. Physico-chemical stability of resuspended nanosystems was monitored during 28 days of storage at 5 °C. Thermal analysis and Fourier-transform infrared spectroscopy were performed to characterize drug state in the systems. Results showed homogeneous particle populations, a suitable mean size for ocular delivery, drug loading ranging from 64.86 to 75.16%, and a controlled release profile. The obtained systems could be promising carriers for ocular drug delivery, legitimating further studies on FA-loaded NPs to confirm efficacy and safety in vitro.
Collapse
|
14
|
Gagliardi A, Voci S, Salvatici MC, Fresta M, Cosco D. Brij-stabilized zein nanoparticles as potential drug carriers. Colloids Surf B Biointerfaces 2021; 201:111647. [PMID: 33639515 DOI: 10.1016/j.colsurfb.2021.111647] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Revised: 02/15/2021] [Accepted: 02/16/2021] [Indexed: 12/13/2022]
Abstract
The current study was designed to provide a preliminary physico-chemical characterization of zein nanosystems prepared with various Brij surfactants (for the first time to the best of our knowledge) as a function of various external stimuli such as temperature, pH, serum incubation and the freeze-drying process. The results demonstrate that when Brijs are characterized by unsaturation (C18), considerable stabilization of the colloidal structure is promoted while the length of the polyethylene glycol fraction does not significantly modulate the physico-chemical properties of the nanosystems. Specifically, dynamic light scattering and nanoparticle tracking analysis demonstrated that the use of 0.2 % w/v of Brij O10 promoted the formation of stable zein nanosystems with mean sizes of ∼150 nm and a narrow size distribution, preserving their structures at various pHs and temperatures. The use of mannitol as cryoprotectant resulted in a formulation that can easily be re-suspended in water after the freeze-drying process. This nanoformulation demonstrated that it efficiently retained different amounts of both hydrophilic and lipophilic compounds and showed a prolonged release of the entrapped molecules. In addition, the nanosystems showed a favorable degree of in vitro safety on various cell lines when a concentration <50 μg/mL of protein was used, demonstrating the potential application of Brij O10-stabilized zein nanoparticles as innovative nanocarriers of several active compounds.
Collapse
Affiliation(s)
- Agnese Gagliardi
- Department of Health Sciences, University "Magna Græcia" of Catanzaro, Campus Universitario "S Venuta", I-88100, Catanzaro, Italy
| | - Silvia Voci
- Department of Health Sciences, University "Magna Græcia" of Catanzaro, Campus Universitario "S Venuta", I-88100, Catanzaro, Italy
| | - Maria Cristina Salvatici
- Institute of Chemistry of Organometallic Compounds (ICCOM)-Electron Microscopy Centre (Ce.M.E.), National Reasearch Council (CNR), via Madonna del Piano n. 10, 50019 Sesto Fiorentino, Firenze, Italy
| | - Massimo Fresta
- Department of Health Sciences, University "Magna Græcia" of Catanzaro, Campus Universitario "S Venuta", I-88100, Catanzaro, Italy
| | - Donato Cosco
- Department of Health Sciences, University "Magna Græcia" of Catanzaro, Campus Universitario "S Venuta", I-88100, Catanzaro, Italy.
| |
Collapse
|
15
|
Sun D, Sun W, Gao SQ, Wei C, Naderi A, Schilb AL, Scheidt J, Lee S, Kern TS, Palczewski K, Lu ZR. Formulation and efficacy of ECO/pRHO-ABCA4-SV40 nanoparticles for nonviral gene therapy of Stargardt disease in a mouse model. J Control Release 2021; 330:329-340. [PMID: 33358976 PMCID: PMC9066847 DOI: 10.1016/j.jconrel.2020.12.010] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 12/07/2020] [Accepted: 12/09/2020] [Indexed: 01/13/2023]
Abstract
It is still a challenge to develop gene replacement therapy for retinal disorders caused by mutations in large genes, such as Stargardt disease (STGD). STGD is caused by mutations in ABCA4 gene. Previously, we have developed an effective non-viral gene therapy using self-assembled nanoparticles of a multifunctional pH-sensitive amino lipid ECO and a therapeutic ABCA4 plasmid containing rhodopsin promoter (pRHO-ABCA4). In this study, we modified the ABCA4 plasmid with simian virus 40 enhancer (SV40, pRHO-ABCA4-SV40) for enhanced gene expression. We also prepared and assessed the formulations of ECO/pDNA nanoparticles using sucrose or sorbitol as a stablilizer to develop consistent and stable formulations. Results demonstrated that ECO formed stable nanoparticles with pRHO-ABCA4-SV40 in the presence of sucrose, but not with sorbitol. The transfection efficiency in vitro increased significantly after introduction of SV40 enhancer for plasmid pCMV-ABCA4-SV40 with a CMV promoter. Sucrose didn't affect the transfection efficiency, while sorbitol resulted in a fluctuation of the in vitro transfection efficiency. Subretinal gene therapy in Abca4-/- mice using ECO/pRHO-ABCA4 and ECO/pRHO-ABCA4-SV40 nanoparticles induced 36% and 29% reduction in A2E accumulation respectively. Therefore, the ECO/pABCA4 based nanoparticles are promising for non-viral gene therapy for Stargardt disease and can be expended for applications in a variety of visual dystrophies with mutated large genes.
Collapse
Affiliation(s)
- Da Sun
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, United States of America
| | - Wenyu Sun
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, United States of America
| | - Song-Qi Gao
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, United States of America
| | - Cheng Wei
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, United States of America
| | - Amirreza Naderi
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, United States of America
| | - Andrew L Schilb
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, United States of America
| | - Josef Scheidt
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, United States of America
| | - Sangjoon Lee
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, United States of America
| | - Timothy S Kern
- Department of Ophthalmology, Physiology & Biophysics, and Chemistry, University of California, Irvine, Irvine, CA 92697, United States of America; Veterans Administration Medical Center Research Service, Long Beach, CA, 90822, United States of America
| | - Krzysztof Palczewski
- Department of Ophthalmology, Physiology & Biophysics, and Chemistry, University of California, Irvine, Irvine, CA 92697, United States of America
| | - Zheng-Rong Lu
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106, United States of America.
| |
Collapse
|
16
|
Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. NANOMATERIALS 2020; 10:nano10071403. [PMID: 32707641 PMCID: PMC7408012 DOI: 10.3390/nano10071403] [Citation(s) in RCA: 306] [Impact Index Per Article: 76.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Revised: 07/13/2020] [Accepted: 07/16/2020] [Indexed: 02/06/2023]
Abstract
The complexity of some diseases—as well as the inherent toxicity of certain drugs—has led to an increasing interest in the development and optimization of drug-delivery systems. Polymeric nanoparticles stand out as a key tool to improve drug bioavailability or specific delivery at the site of action. The versatility of polymers makes them potentially ideal for fulfilling the requirements of each particular drug-delivery system. In this review, a summary of the state-of-the-art panorama of polymeric nanoparticles as drug-delivery systems has been conducted, focusing mainly on those applications in which the corresponding disease involves an important morbidity, a considerable reduction in the life quality of patients—or even a high mortality. A revision of the use of polymeric nanoparticles for ocular drug delivery, for cancer diagnosis and treatment, as well as nutraceutical delivery, was carried out, and a short discussion about future prospects of these systems is included.
Collapse
|
17
|
Bonaccorso A, Gigliobianco MR, Pellitteri R, Santonocito D, Carbone C, Di Martino P, Puglisi G, Musumeci T. Optimization of Curcumin Nanocrystals as Promising Strategy for Nose-to-Brain Delivery Application. Pharmaceutics 2020; 12:E476. [PMID: 32456163 PMCID: PMC7284456 DOI: 10.3390/pharmaceutics12050476] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2020] [Revised: 05/18/2020] [Accepted: 05/21/2020] [Indexed: 12/15/2022] Open
Abstract
Intranasal (IN) drug delivery is recognized to be an innovative strategy to deliver drugs to the Central Nervous System. One of the main limitations of IN dosing is the low volume of drug that can be administered. Accordingly, two requirements are necessary: the drug should be active at a low dosage, and the drug solubility in water must be high enough to accommodate the required dose. Drug nanocrystals may overcome these limitations; thus, curcumin was selected as a model drug to prepare nanocrystals for potential IN administration. With this aim, we designed curcumin nanocrystals (NCs) by using Box Behnken design. A total of 51 formulations were prepared by the sonoprecipitation method. Once we assessed the influence of the independent variables on nanocrystals' mean diameter, the formulation was optimized based on the desirability function. The optimized formulation was characterized from a physico-chemical point of view to evaluate the mean size, zeta potential, polidispersity index, pH, osmolarity, morphology, thermotropic behavior and the degree of crystallinity. Finally, the cellular uptake of curcumin and curcumin NCs was evaluated on Olfactory Ensheathing Cells (OECs). Our results showed that the OECs efficiently took up the NCs compared to the free curcumin, showing that NCs can ameliorate drug permeability.
Collapse
Affiliation(s)
- Angela Bonaccorso
- Department of Drug Sciences, University of Catania; V.le Andrea Doria, 6, 95125 Catania, Italy; (D.S.); (C.C.); (G.P.); (T.M.)
| | - Maria Rosa Gigliobianco
- School of Pharmacy, University of Camerino, Via. S. Agostino 1, 62032 Camerino (MC), Italy; (M.R.G.); (P.D.M.)
| | - Rosalia Pellitteri
- Institute for Biomedical Research and Innovation, National Research Council, Via Paolo Gaifami 18, 95126 Catania, Italy;
| | - Debora Santonocito
- Department of Drug Sciences, University of Catania; V.le Andrea Doria, 6, 95125 Catania, Italy; (D.S.); (C.C.); (G.P.); (T.M.)
| | - Claudia Carbone
- Department of Drug Sciences, University of Catania; V.le Andrea Doria, 6, 95125 Catania, Italy; (D.S.); (C.C.); (G.P.); (T.M.)
| | - Piera Di Martino
- School of Pharmacy, University of Camerino, Via. S. Agostino 1, 62032 Camerino (MC), Italy; (M.R.G.); (P.D.M.)
| | - Giovanni Puglisi
- Department of Drug Sciences, University of Catania; V.le Andrea Doria, 6, 95125 Catania, Italy; (D.S.); (C.C.); (G.P.); (T.M.)
| | - Teresa Musumeci
- Department of Drug Sciences, University of Catania; V.le Andrea Doria, 6, 95125 Catania, Italy; (D.S.); (C.C.); (G.P.); (T.M.)
| |
Collapse
|
18
|
Nanomedicines for the Delivery of Antimicrobial Peptides (AMPs). NANOMATERIALS 2020; 10:nano10030560. [PMID: 32244858 PMCID: PMC7153398 DOI: 10.3390/nano10030560] [Citation(s) in RCA: 70] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/09/2020] [Revised: 03/12/2020] [Accepted: 03/13/2020] [Indexed: 01/09/2023]
Abstract
Microbial infections are still among the major public health concerns since several yeasts and fungi, and other pathogenic microorganisms, are responsible for continuous growth of infections and drug resistance against bacteria. Antimicrobial resistance rate is fostering the need to develop new strategies against drug-resistant superbugs. Antimicrobial peptides (AMPs) are small peptide-based molecules of 5–100 amino acids in length, with potent and broad-spectrum antimicrobial properties. They are part of the innate immune system, which can represent a minimal risk of resistance development. These characteristics contribute to the description of these molecules as promising new molecules in the development of new antimicrobial drugs. However, efforts in developing new medicines have not resulted in any decrease of drug resistance yet. Thus, a technological approach on improving existing drugs is gaining special interest. Nanomedicine provides easy access to innovative carriers, which ultimately enable the design and development of targeted delivery systems of the most efficient drugs with increased efficacy and reduced toxicity. Based on performance, successful experiments, and considerable market prospects, nanotechnology will undoubtedly lead a breakthrough in biomedical field also for infectious diseases, as there are several nanotechnological approaches that exhibit important roles in restoring antibiotic activity against resistant bacteria.
Collapse
|
19
|
Ahmad N, Ahmad R, Alrasheed RA, Almatar HMA, Al-Ramadan AS, Amir M, Sarafroz M. Quantification and Evaluations of Catechin Hydrate Polymeric Nanoparticles Used in Brain Targeting for the Treatment of Epilepsy. Pharmaceutics 2020; 12:pharmaceutics12030203. [PMID: 32120778 PMCID: PMC7150881 DOI: 10.3390/pharmaceutics12030203] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2020] [Revised: 02/22/2020] [Accepted: 02/24/2020] [Indexed: 01/02/2023] Open
Abstract
To formulate novel chitosan (CS)-coated-PLGA-nanoparticles (NPs) using a central composite design approach and use them in order to improve brain bioavailability for catechin hydrate (CH) through direct nose-to-central nervous system (CNS) delivery for the evaluation of a comparative biodistribution study of CH by the newly developed ultra high performance liquid chromatography mass spectroscopy and mass spectroscopy (UHPLC-MS/MS) method in the treatment of epilepsy. For PLGA-NPs' preparation, a double emulsion-solvent evaporation method was used, where a four-factor, three-level central composite design was used to obtain the best nanoformulation. For the optimization, four independent variables were chosen, that is, PLGA, polyvinyl alcohol (PVA), sonication time, and temperature. The optimized PLGA-NPs were further coated with chitosan and assessed for drug release, nasal permeation study, as well as a comparative pharmacokinetic and pharmacodynamic study. Independent and dependent variables helped to optimize the best nanoformulation based on the composition of PLGA (50.0 mg), PVA (1.10%), sonication time (90.0 s), and temperature (25.0 °C). The values of dependent variables were observed, such as polydispersity index (PDI), particle size, and zeta potential (ZP)-that is, 0.106 ± 0.01, 93.46 ± 3.94 nm, and -12.63 ± 0.08 mV, respectively. The ZPs of CS-coated PLGA-NPs were changed from negative to positive value with some alteration in the distribution of particle size. Excellent mucoadhesive-nature of CS-CH-PLGA-NPs as compared with CH-S and CH-PLGA-NPs was seen, with a retention time of 0.856 min and m/z of 289.23/245.20 for CH, together with a retention time of 1.04 min and m/z of 301.21/151.21 for Quercetin as an internal standard (IS). For a linear range (1-1000 ng mL-1), % accuracy (93.07-99.41%) and inter- and intraday % precision (0.39-4.90%) were determined. The improved Cmax with area under curve (AUC)0-24 was found to be highly significant (p < 0.001) in Wistar rats' brain as compared with the i.n. and i.v. treated group based on the pharmacokinetics (PK) results. Furthermore, CS-CH-PLGA-NPs were found to be more significant (p < 0.001) for the treatment of seizure threshold rodent models, that is, increasing current electroshock and pentylenetetrazole-induced seizures. A significant role of CS-CH-PLGA-NPs was observed, that is, p < 0.001, for the enhancement of brain bioavailability and the treatment of epilepsy.
Collapse
Affiliation(s)
- Niyaz Ahmad
- Department of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 314441, Saudi Arabia; (R.A.A.); (H.M.A.A.); (A.S.A.-R.)
- Department of Pharmaceutical Chemistry, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 314441, Saudi Arabia;
- Correspondence: or ; Tel.: +966-13-333-5541 or +966-531203626; Fax: +966-13-333-0290
| | - Rizwan Ahmad
- Department of Natural Products and Alternative Medicine, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 314441, Saudi Arabia; (R.A.); (M.A.)
| | - Ridha Abdullah Alrasheed
- Department of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 314441, Saudi Arabia; (R.A.A.); (H.M.A.A.); (A.S.A.-R.)
| | - Hassan Mohammed Ali Almatar
- Department of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 314441, Saudi Arabia; (R.A.A.); (H.M.A.A.); (A.S.A.-R.)
| | - Abdullah Sami Al-Ramadan
- Department of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 314441, Saudi Arabia; (R.A.A.); (H.M.A.A.); (A.S.A.-R.)
| | - Mohd Amir
- Department of Natural Products and Alternative Medicine, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 314441, Saudi Arabia; (R.A.); (M.A.)
| | - Md Sarafroz
- Department of Pharmaceutical Chemistry, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 314441, Saudi Arabia;
| |
Collapse
|
20
|
Ahmad N, Ahmad R, Al Qatifi S, Alessa M, Al Hajji H, Sarafroz M. A bioanalytical UHPLC based method used for the quantification of Thymoquinone-loaded-PLGA-nanoparticles in the treatment of epilepsy. BMC Chem 2020; 14:10. [PMID: 32083254 PMCID: PMC7023730 DOI: 10.1186/s13065-020-0664-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Accepted: 01/22/2020] [Indexed: 12/19/2022] Open
Abstract
To formulate a nanoformulation (PLGA-NPs) and to improve brain bioavailability for thymoquinone (THQ) through intranasal (i.n.) drug delivery, using a newly UHPLC-PDA developed the method and validated. Five different THQ-PLGA-NPs (THQ-N1 to THQ-N5) were prepared by emulsion solvent evaporation method. A new UHPLC method developed and validated for biodistribution studies in the rat’s brain, lungs and plasma. Optimized-THQ-N1-NPs showed a particle size of 97.36 ± 2.01 nm with a low PDI value of 0.263 ± 0.004, ZP of − 17.98 ± 1.09, EE of 82.49 ± 2.38% and DL of 5.09 ± 0.13%. THQ-N1-NPs showed sustained release pattern via in vitro release profile. A bioanalytical method was developed by UHPLC-PDA and validated for the evaluation of pharmacokinetics parameters, biodistribution studies, brain drug-targeting potential (89.89 ± 9.38%), and brain-targeting efficiency (8075.00 ± 113.05%) studies through intranasal administration which showed an improved THQ-brain- bioavailability, compared to i.v. Moreover, THQ-PLGA-NPs improved the seizure threshold treatment i.e. epilepsy increasing current electroshock (ICES) rodent models induced seizures in rats. A significant role of THQ-PLGA-NPs with high brain targeting efficiency of the nanoformulations was established. The reported data supports the treatment of epilepsy.![]()
Collapse
Affiliation(s)
- Niyaz Ahmad
- 1Department of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia.,2Department of Pharmaceutical Chemistry, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia
| | - Rizwan Ahmad
- 3Department of Natural Products and Alternative Medicine, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia
| | - Sadiq Al Qatifi
- 1Department of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia
| | - Mahdi Alessa
- 1Department of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia
| | - Hassan Al Hajji
- 1Department of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia
| | - Md Sarafroz
- 2Department of Pharmaceutical Chemistry, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia
| |
Collapse
|
21
|
Grimaudo MA, Amato G, Carbone C, Diaz-Rodriguez P, Musumeci T, Concheiro A, Alvarez-Lorenzo C, Puglisi G. Micelle-nanogel platform for ferulic acid ocular delivery. Int J Pharm 2019; 576:118986. [PMID: 31870956 DOI: 10.1016/j.ijpharm.2019.118986] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 12/04/2019] [Accepted: 12/19/2019] [Indexed: 12/26/2022]
Abstract
Corneal wound healing after a trauma or a chemical injury has been shown to correlate with antioxidant levels at the ocular surface. However, ocular bioavailability of efficient antioxidants (e.g. ferulic acid) after topical administration is limited by their poor solubility, low stability and short residence time. The aim of this work was to formulate ferulic acid in a nanocomposite platform composed of nanogels and micelles for efficient delivery to cornea. Solubility enhancement factor of ferulic acid was found to be equal to 1.9 ± 0.3 and 3.4 ± 0.3 for 50 and 100 mg/ml Pluronic® F68 micellar solutions. Hyaluronan was added to blank and ferulic acid loaded micelles, and then cross-linked with ε-polylysine. Hyaluronan nanogels showed dimensions of ~300 nm with positive zeta potential values. The formulations were characterized in terms of rheological behavior, biocompatibility, wound healing properties, ferulic acid release pattern and penetration into excised bovine corneas. In comparison to Pluronic® micelles that released ferulic acid rapidly, micelle-nanogel composites sustained the release up to 2 days. Furthermore, the micelle-nanogel formulation favored in vitro wound closure promoting fibroblasts growth and ex vivo accumulation of ferulic acid into both healthy and damaged corneas (>100 µg/cm2).
Collapse
Affiliation(s)
- Maria Aurora Grimaudo
- Laboratory of Drug Delivery Technology, Department of Drug Sciences, University of Catania, Catania, Italy; Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
| | - Giovanni Amato
- Laboratory of Drug Delivery Technology, Department of Drug Sciences, University of Catania, Catania, Italy.
| | - Claudia Carbone
- Laboratory of Drug Delivery Technology, Department of Drug Sciences, University of Catania, Catania, Italy
| | - Patricia Diaz-Rodriguez
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Teresa Musumeci
- Laboratory of Drug Delivery Technology, Department of Drug Sciences, University of Catania, Catania, Italy
| | - Angel Concheiro
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Carmen Alvarez-Lorenzo
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Giovanni Puglisi
- Laboratory of Drug Delivery Technology, Department of Drug Sciences, University of Catania, Catania, Italy
| |
Collapse
|
22
|
Ahmad N, Ahmad R, Alam MA, Ahmad FJ, Rub RA. Quantification and Evaluation of Glycyrrhizic Acid-loaded Surface Decorated Nanoparticles by UHPLC-MS/MS and used in the Treatment of Cerebral Ischemia. CURR PHARM ANAL 2019. [DOI: 10.2174/1573412914666180530073613] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
Glycyrrhizic Acid (GRA), a potent antioxidant triterpene saponin glycoside
and neuroprotective properties exhibits an important role in the treatment of neurological disorders i.e.
cerebral ischemia. GRA is water soluble, therefore it’s have low bioavailability in the brain.
Objective:
To enhance brain bioavailability for intranasally administered Glycyrrhizic Acidencapsulated-
chitosan-coated-PCL-Nanoparticles (CS-GRA-PCL-NPs).
Methods:
Chitosan-coated-PCL-Nanoparticles (CS-PCL-NPs) were developed through double emulsification-
solvent evaporation technique and further characterized for particle size, zeta potential, size
distribution, encapsulation efficiency as well as in vitro drug release. UPLC triple quadrupole Qtrap
MS/MS method was developed to evaluate brain-drug uptake for optimized CS-GRA-PCL-NPs and to
determine its pharmacokinetic in rat’s brain as well as plasma.
Results:
Mean particles size (231.47±7.82), polydispersity index (PDI) i.e. (0.216±0.030) and entrapment
efficiency (65.69±5.68) was determined for developed NPs. UPLC triple quadrupole Qtrap MS/MS
method study showed a significantly high mucoadhesive potential of CS-GRA-PCL-NPs and least for
conventional and homogenized nanoformulation; elution time for GRA and internal standard (IS) Hydrocortisone
as 0.37 and 1.94 min at m/z 821.49/113.41 and 363.45/121.40 were observed, respectively. Furthermore,
intra and inter-assay (%CV) of 0.49-5.48, %accuracy (90.00-99.09%) as well as a linear dynamic
range (10.00 ng/mL -2000.0 ng/mL), was observed. Pharmacokinetic studies in Wistar rat brain
exhibited a high AUC0-24 alongwith an amplified Cmax (p** < 0.01) as compared to i.v. treated group.
Conclusion:
Intranasal administration of developed CS-coated-GRA-loaded-PCL-NPs enhanced the
drug bioavailability in rat brain along with successfully UPLC-MS/MS method and thus preparation of
GRA-NPs may help treat cerebral ischemia effectively. The toxicity studies performed at the end
revealed safe nature of optimized nanoformulation.
Collapse
Affiliation(s)
- Niyaz Ahmad
- Department of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
| | - Rizwan Ahmad
- Department of Natural Products and Alternative Medicine, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
| | - Md Aftab Alam
- Department of Pharmaceutics, School of Medical and Allied Sciences, Galgotias University, Gautam Budh Nagar, Greater Noida-201310, India
| | - Farhan Jalees Ahmad
- Nanomedicine Lab, Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, Hamdard Nagar, New Delhi, India
| | - Rehan Abdur Rub
- Nanomedicine Lab, Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, Hamdard Nagar, New Delhi, India
| |
Collapse
|
23
|
Design and optimization of PEGylated nanoparticles intended for Berberine Chloride delivery. J Drug Deliv Sci Technol 2019. [DOI: 10.1016/j.jddst.2019.05.012] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
24
|
de Matos SP, Teixeira HF, de Lima ÁAN, Veiga-Junior VF, Koester LS. Essential Oils and Isolated Terpenes in Nanosystems Designed for Topical Administration: A Review. Biomolecules 2019; 9:biom9040138. [PMID: 30959802 PMCID: PMC6523335 DOI: 10.3390/biom9040138] [Citation(s) in RCA: 58] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2019] [Revised: 04/01/2019] [Accepted: 04/02/2019] [Indexed: 12/16/2022] Open
Abstract
Essential oils are natural products with a complex composition. Terpenes are the most common class of chemical compounds present in essential oils. Terpenes and the essential oils containing them are widely used and investigated by their pharmacological properties and permeation-enhancing ability. However, many terpenes and essential oils are sensitive to environmental conditions, undergoing volatilization and chemical degradation. In order to overcome the chemical instability of some isolated terpenes and essential oils, the encapsulation of these compounds in nanostructured systems (polymeric, lipidic, or molecular complexes) has been employed. In addition, nanoencapsulation can be of interest for pharmaceutical applications due to its capacity to improve the bioavailability and allow the controlled release of drugs. Topical drug administration is a convenient and non-invasive administration route for both local and systemic drug delivery. The present review focuses on describing the current status of research concerning nanostructured delivery systems containing isolated terpenes and/or essential oils designed for topical administration and on discussing the use of terpenes and essential oils either for their biological activities or as permeation enhancers in pharmaceutic formulations.
Collapse
Affiliation(s)
- Sheila P de Matos
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Av. Ipiranga, 2752, Porto Alegre 90610-000, Brazil.
| | - Helder F Teixeira
- Programa de Pós-Graduação em Ciências Farmacêuticas, Departamento de Farmácia, Universidade Federal do Rio Grande do Norte, Av. General Cordeiro de Farias, s/n, Petrópolis, Natal 59012-570, Brazil.
| | - Ádley A N de Lima
- Programa de Pós-Graduação em Ciências Farmacêuticas, Departamento de Farmácia, Universidade Federal do Rio Grande do Norte, Av. General Cordeiro de Farias, s/n, Petrópolis, Natal 59012-570, Brazil.
| | - Valdir F Veiga-Junior
- Departamento de Engenharia Química, Instituto Militar de Engenharia, Praça Gen. Tibúrcio, 80, Praia Vermelha, Urca, Rio de Janeiro 22290-270, Brazil.
| | - Letícia S Koester
- Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Av. Ipiranga, 2752, Porto Alegre 90610-000, Brazil.
| |
Collapse
|
25
|
Musumeci T, Bonaccorso A, Puglisi G. Epilepsy Disease and Nose-to-Brain Delivery of Polymeric Nanoparticles: An Overview. Pharmaceutics 2019; 11:E118. [PMID: 30871237 PMCID: PMC6471219 DOI: 10.3390/pharmaceutics11030118] [Citation(s) in RCA: 57] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2019] [Revised: 03/04/2019] [Accepted: 03/06/2019] [Indexed: 02/07/2023] Open
Abstract
Epilepsy is the fourth most common global neurological problem, which can be considered a spectrum disorder because of its various causes, seizure types, its ability to vary in severity and the impact from person to person, as well as its range of co-existing conditions. The approaches to drug therapy of epilepsy are directed at the control of symptoms by chronic administration of antiepileptic drugs (AEDs). These AEDs are administered orally or intravenously but alternative routes of administration are needed to overcome some important limits. Intranasal (IN) administration represents an attractive route because it is possible to reach the brain bypassing the blood brain barrier while the drug avoids first-pass metabolism. It is possible to obtain an increase in patient compliance for the easy and non-invasive route of administration. This route, however, has some drawbacks such as mucociliary clearance and the small volume that can be administered, in fact, only drugs that are efficacious at low doses can be considered. The drug also needs excellent aqueous solubility or must be able to be formulated using solubilizing agents. The use of nanomedicine formulations able to encapsulate active molecules represents a good strategy to overcome several limitations of this route and of conventional drugs. The aim of this review is to discuss the innovative application of nanomedicine for epilepsy treatment using nose-to-brain delivery with particular attention focused on polymeric nanoparticles to load drugs.
Collapse
Affiliation(s)
- Teresa Musumeci
- Department of Drug Sciences, University of Catania; V.le Andrea Doria, 6, 95125 Catania, Italy.
| | - Angela Bonaccorso
- Department of Drug Sciences, University of Catania; V.le Andrea Doria, 6, 95125 Catania, Italy.
| | - Giovanni Puglisi
- Department of Drug Sciences, University of Catania; V.le Andrea Doria, 6, 95125 Catania, Italy.
| |
Collapse
|
26
|
Ahmad N. Rasagiline-encapsulated chitosan-coated PLGA nanoparticles targeted to the brain in the treatment of parkinson's disease. J LIQ CHROMATOGR R T 2017. [DOI: 10.1080/10826076.2017.1343735] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Niyaz Ahmad
- Department of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University (Formerly University of Dammam), Dammam, Kingdom of Saudi Arabia
- Department of Pharmaceutical Chemistry, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University (Formerly University of Dammam), Dammam, Kingdom of Saudi
| |
Collapse
|